<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>3 Healthcare Stocks We’re Skeptical Of</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>3 Healthcare Stocks We’re Skeptical Of</h1>
  <ul>
<li>
<ul>
<li>Revenue base of $1.28 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale - Low free cash flow margin of 4% for the last five years gives it little breathing room, constrainin</li>
</ul>
</li>
<li>
<ul>
<li>Customers postponed purchases of its products and services this cycle as its revenue declined by 2.9% annually over the last two years - Organic revenue growth fell short of our benchmarks over the past two years and i</li>
</ul>
</li>
<li>Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen</li>
<li>Penumbra (PEN) Market Cap: $10.98 billion Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vasc</li>
<li>Hologic (HOLX) Market Cap: $14.85 billion As a pioneer in 3D mammography technology that has revolutionized breast cancer detection, Hologic (NASDAQ:HOLX) develops and manufactures diagnostic products, medical imaging sy</li>
<li>Danaher (DHR) Market Cap: $143.4 billion Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized</li>
<li>Why Does PEN Worry Us?</li>
</ul>
<p><a href="https://finance.yahoo.com/news/3-healthcare-stocks-skeptical-043351121.html">Source</a> · 2025-09-08T04:33:51+00:00</p>
</body>
</html>